MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-DL-06-0000078
Avrohn Pharma (I) Limited
Avrohn Pharma (I) Limited - pharma in Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹13.49 Cr
▲ 69% YoY
Net profit · FY 2025
₹67.09 Lakh
Net margin 5%
EBITDA · FY 2025
₹1.48 Cr
EBITDA margin 11%
Authorised capital
₹5 Lakh
Registered with MCA
Paid-up capital
₹5 Lakh
Issued & subscribed
Open charges
₹3.37 Cr
Satisfied ₹60 Lakh
Company age
14 yrs
Est. 2012
Directors on board
3
As per MCA filings
About Avrohn Pharma (I) Limited
Data last updated:
Avrohn Pharma (I) Limited is a public limited company based in Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 12 March 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24119DL2012PLC232680. Its GSTIN is 07AALCA7515J1ZG (Delhi).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors including Neeta Verender Kumar Gupta and Virender Kumar Gupta.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at G – 216 Hall No. 1 Ground Floor Dakka Village Near Kingsway Camp, Delhi, India – 110009.
As per the financials filed for FY 2025, the company reported a revenue of ₹13.49 Cr, a growth of 69% compared to the previous year. For the same year it recorded a net profit of ₹67.09 Lakh (net margin 5%) and EBITDA of ₹1.48 Cr (EBITDA margin 11%). Revenue has grown at a compounded annual rate (CAGR) of 42% over three years and 32% over five years.
As per MCA filings, the company has open charges of ₹3.37 Cr and satisfied charges of ₹60 Lakh on record.
Avrohn Pharma (I) Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-DL-06-0000078). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
CIN U24119DL2012PLC232680
Registration Number 232680
Incorporation Date 12 March 2012
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification MSME
Udyam Registration UDYAM-DL-06-0000078
Key People
Neeta Verender Kumar Gupta Director Virender Kumar Gupta Director Abhishek Gupta Director Recognitions & Rankings of Avrohn Pharma (I)
Contact details
Avrohn Pharma (I) Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressG – 216 Hall No. 1 Ground Floor Dakka Village Near Kingsway Camp, Delhi, India – 110009
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Avrohn Pharma (I) Limited, buy the company report.
Comprehensive company report
Avrohn Pharma (I) Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Avrohn Pharma (I) is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Avrohn Pharma (I) Limited, buy the company report.
Financials of Avrohn Pharma (I) Limited
FY 2025 filings availableAvrohn Pharma (I) Limited reported revenue of ₹13.49 Cr (up 69% YoY) for FY 2025.
Revenue · FY 2025
₹13.49 Cr ▲ 69%
Net profit · FY 2025
₹67.09 Lakh margin 5%
EBITDA · FY 2025
₹1.48 Cr margin 11%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 69%
3 years · compounded
▲ 42%
5 years · compounded
▲ 32%
EBITDA CAGR growth
1 year
▲ 159%
3 years · compounded
▲ 101%
5 years · compounded
▲ 23%
Revenue has grown at a compounded annual rate (CAGR) of 32% over five years, including 69% growth in the latest year. EBITDA rose 159% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.48 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹67.09 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11% | ||||
| Net Profit Margin | 5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Avrohn Pharma (I) Limited, buy the company report.
Board of directors of Avrohn Pharma (I) Limited
Avrohn Pharma (I) has 3 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Neeta Verender Kumar Gupta | Director | 26 Mar 2022 | 4 Years 7 Months | Current |
| Virender Kumar Gupta | Director | 12 Mar 2012 | 14 Years 7 Months | Current |
| Abhishek Gupta | Director | 12 Mar 2012 | 14 Years 7 Months | Current |
Peer comparison
Avrohn Pharma (I) Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sri Devi Distributors Private Limited | ₹13.52 Cr (FY 2024) | 30.0% | Chennai, Tamil Nadu, India | |||
| Ryvis Pharma Private Limited | ₹13.51 Cr (FY 2024) | 44.0% | New Delhi, Delhi, India | |||
| Vivan Acidchem Private Limited | ₹13.5 Cr (FY 2022) | 6.0% | Indore, Madhya Pradesh, India | |||
| Avrohn Pharma (I) Limitedthis company | ₹13.49 Cr (FY 2025) | ₹67.09 Lakh | 5% | 69.0% | Delhi, India | |
| Bansal Drugs Private Limited | ₹13.41 Cr (FY 2024) | 37.0% | Uttar Pradesh, India | |||
| Kaveri Medi House Private Limited | ₹13.33 Cr (FY 2024) | -3.0% | Davanagere, Karnataka, India |
To see the full peer comparison of Avrohn Pharma (I) Limited, buy the company report.
Auditor
Avrohn Pharma (I) Limited is audited by A KAY MEHRA & CO for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| A KAY MEHRA & CO | FY 2022 | 050004C |
Shareholding
The shareholding of Avrohn Pharma (I) Limited is on record for 5 financial years, the latest being FY 2022, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Avrohn Pharma (I) Limited, buy the company report.
Charges & borrowings
Open charges
₹3.37 Cr
Satisfied charges
₹60 Lakh
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 15 Nov 2025 | 101240020 | Others | ₹35 Lakh | Open | |
| 17 Jun 2025 | 101109968 | Others | ₹25 Lakh | Open | |
| 11 Mar 2025 | 101064316 | Canara Bank | ₹29.27 Lakh | Open | |
| 06 Feb 2024 | 100874919 | Canara Bank | ₹19 Lakh | Open | |
| 06 Nov 2023 | 100817488 | Canara Bank | ₹1.95 Cr | Open |
To see the full charge records of Avrohn Pharma (I) Limited, buy the company report.
Total charge records: 8 View all charges
Legal cases
No court or tribunal cases involving Avrohn Pharma (I) Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Avrohn Pharma (I) Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Avrohn Pharma (I) has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AALCA7515J1ZG | Delhi | Active | 25 Jul 2017 |
To see the full GST registrations and return filing status of Avrohn Pharma (I) Limited, buy the company report.
Recent activity
Avrohn Pharma (I) Limited has 4 board changes on record since 2012: 3 appointments and 1 cessation. The latest: Garima Jain ceased to be Director on 26 Mar 2022.
Charges
A charge with Others amounted to Rs. 35.00 Lakh with Charge ID 101240020 was registered on 15 Nov 2025.
AGM
Avrohn Pharma (I) Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 25.00 Lakh with Charge ID 101109968 was registered on 17 Jun 2025.
Filing
Avrohn Pharma (I) Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi I.
Charges
A charge with Canara Bank amounted to Rs. 29.27 Lakh with Charge ID 101064316 was registered on 11 Mar 2025.
Charges
A charge registered on 28 Sep 2022 via Charge ID 100676073 with Hdfc Bank Limited was fully satisfied on 24 Sep 2024.
Charges
A charge with Canara Bank of Rs. 195.00 Lakh registered on 06 Nov 2023 with Charge ID 100817488 was modified on 10 Sep 2024.
Charges
A charge with Canara Bank amounted to Rs. 19.00 Lakh with Charge ID 100874919 was registered on 06 Feb 2024.
Charges
A charge with Canara Bank amounted to Rs. 195.00 Lakh with Charge ID 100817488 was registered on 06 Nov 2023.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 60.00 Lakh with Charge ID 100676073 was registered on 28 Sep 2022.
Ceased
Garima Jain ceased to be Director.
Appointed
Neeta Verender Kumar Gupta was appointed as Director.
5 earlier events are in the company report.
Frequently asked questions
Avrohn Pharma (I) is an active public limited company based in Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 12 March 2012 (14+ years old) and is registered under CIN U24119DL2012PLC232680.
Avrohn Pharma (I) has 3 current directors:
- Neeta Verender Kumar Gupta - Director
- Virender Kumar Gupta - Director
- Abhishek Gupta - Director
The latest financial statements of Avrohn Pharma (I) on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Avrohn Pharma (I) is 07AALCA7515J1ZG, registered in Delhi.
The CIN (Corporate Identification Number) of Avrohn Pharma (I) is U24119DL2012PLC232680. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Avrohn Pharma (I) was incorporated on 12 March 2012, making it 14+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Avrohn Pharma (I) by revenue are Sri Devi Distributors Private Limited, Ryvis Pharma Private Limited, Vivan Acidchem Private Limited, Bansal Drugs Private Limited, Kaveri Medi House Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Garima Jain ceased to be Director on 26 Mar 2022. Neeta Verender Kumar Gupta was appointed as Director on 26 Mar 2022. Abhishek Gupta was appointed as Director on 12 Mar 2012. Avrohn Pharma (I) has 4 board changes on record in total.
Yes, Avrohn Pharma (I) is registered as an MSME under Udyam registration (number: UDYAM-DL-06-0000078).
The registered office of Avrohn Pharma (I) is at G – 216 Hall No. 1 Ground Floor Dakka Village Near Kingsway Camp, Delhi, India – 110009.
Avrohn Pharma (I) operates in the pharma industry, in the pharmaceutical retailers and distributors segment.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages